LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
 to Present at the 9th Annual Biotech Showcase in San Francisco - EconoTimes)
SHANGHAI, China and CUPERTINO, Calif., Jan. 04, 2017 -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biomedicine firm engaged in the development of effective immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that the Company has been selected to present at the 9th Annual Biotech Showcase to be held from January 9-11, 2017 in San Francisco, CA. The Company will present an update on its operations, activities and clinical research progress.
| Conference: | 9th Annual BioTech Showcase 2017 | ||
| Date: | Tuesday, January 10, 2017 | ||
| Time: | 10:30 AM PST | ||
| Presenter: | Tony (Bizuo) Liu, Chief Executive Officer | ||
| Location: | Room 2 (Ballroom Level) Hilton San Francisco Union Square, 333 O'Farrell Street, San Francisco, CA | ||
| Live webcast: | https://event.webcasts.com/viewer/event.jsp?ei=1130607 | ||
Company management will attend the conference and be available for discussions. To arrange one-to-one meetings with management, please contact [email protected]. The presented material will be available on the Company website following the presentations.
About Cellular Biomedicine Group (CBMG)
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of cancer and degenerative diseases. Our immuno-oncology and stem cell projects are the result of research and development by CBMG’s scientists and clinicians from both China and the United States. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com.
Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include risks inherent in doing business, trends affecting the global economy, including the devaluation of the RMB by China in August 2015 and other risks detailed from time to time in CBMG’s reports filed with the Securities and Exchange Commission, quarterly reports on form 10-Q, current reports on form 8-K and annual reports on form 10-K. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.
Contacts: Sarah Kelly Director of Corporate Communications, CBMG +1 408-973-7884 [email protected] Vivian Chen Managing Director Investor Relations, Grayling +1 347 481-3711 [email protected]
